Bempedoic acid: what prospective uses? - Université de Lorraine Access content directly
Journal Articles European Heart Journal Supplements Year : 2023

Bempedoic acid: what prospective uses?

Abstract

Abstract There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can’t reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile.
Fichier principal
Vignette du fichier
suad012.pdf (158.89 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04144672 , version 1 (28-06-2023)

Licence

Identifiers

Cite

Ilaria Jacomelli, Luca Monzo, Germana Panattoni, Chiara Lanzillo, Marco Rebecchi, et al.. Bempedoic acid: what prospective uses?. European Heart Journal Supplements, 2023, 25 (Supplement_C), pp.C109-C111. ⟨10.1093/eurheartjsupp/suad012⟩. ⟨hal-04144672⟩
1 View
4 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More